KPF
NVLN

K2 Principal Fund’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

K2 Principal Fund’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-89,900
Closed -$632K – 382
2017
Q3 		$632K Buy
+89,900
New +$720K 0.04% 239

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

K2 Principal Fund's NVLN Position: Q2 2017 in Review

K2 Principal Fund sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2017, closing a stake of 49,350 shares — an estimated $530K sold.

K2 Principal Fund first reported a position in NVLN in Q4 2016 and held it in 2 quarters. The position peaked at $2.27M in Q4 2016. 76 funds tracked by Wall St. Rank hold NVLN as of Q2 2017.

  • K2 Principal Fund reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2017 after selling out during the quarter.
  • K2 Principal Fund sold 49,350 Novelion Therapeutics Inc. Common Shares shares in Q2 2017, an estimated $530K.
  • K2 Principal Fund first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 2 quarters.
  • K2 Principal Fund's Novelion Therapeutics Inc. Common Shares position peaked at $2.27M in Q4 2016.
  • 76 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2017.

Based on K2 Principal Fund's 13F filing for Q2 2017, filed 11 Aug 2017.